NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • A Guide to What We Do
    • Activities during COVID-19
    • Strategic Partnership Board
    • Steering Committee
    • Promoting Equality, Diversity and Inclusion in Research
    • Current Vacancies
    • Contact Us
    • Stay in Touch
  • Research
        • OUR 20 RESEARCH THEMES

        • Antimicrobial Resistance and Modernising Microbiology
        • Cardiovascular
        • Clinical Informatics and Big Data
        • Diabetes and Metabolism
        • Gastroenterology and Mucosal Immunity
        • Genomic Medicine
        • Haematology and Stem Cells
        • Imaging
        • Molecular Diagnostics
        • Multi-Modal Cancer Therapies
        • Multi-Morbidity and Long-Term Conditions
        • Musculoskeletal
        • Neurological Conditions
        • Obesity, Diet and Lifestyle
        • Partnerships for Health, Wealth and Innovation
        • Respiratory
        • Stroke and Vascular Dementia
        • Surgical Innovation and Evaluation
        • Technology and Digital Health
        • Vaccines for Emerging and Endemic Diseases
        • Oxford Biomedical Research Centre activities during COVID-19
  • Patient & Public Involvement
    • Getting involved with research
    • Researcher Guidance
    • Post an opportunity for patient and public involvement
  • Training Hub
    • Training Hub Overview
    • Clinical Academic Pathway
    • Internships
    • Preparatory Research Fellowships
    • Senior Research Fellowships
    • Research Training Bursaries
    • Doctoral Awards
    • Post-Doctoral Awards
    • Other funding
    • Leadership Training
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • What Can We Do For Your Organisation?
    • Who Do We Work With?
    • IP and Licensing
    • Contacts for Industry
  • Videos
  • News
  • Events

News

You are here: Home > Multi-Modal Cancer Therapies > New multi-cancer early detection blood test study opens

New multi-cancer early detection blood test study opens

17 September 2021 · Listed under Multi-Modal Cancer Therapies

Volunteers in Oxfordshire are taking part in a new study that will trial a revolutionary new blood test that can detect more than 50 types of cancer before symptoms appear.

The aim of the SYMPLIFY study, which is being led by the University of Oxford and is open at Oxford University Hospitals (OUH), is to demonstrate how the Galleri test, which checks for the earliest signs of cancer in the blood, could be used to increase cancer detection rates and improve diagnostic pathways.

Photo: Karolina Grabowska via Pexels

Already 500 participants across the Thames Valley have been recruited to take the new multi-cancer early detection (MCED) test, and this could rise to 1,000 by the end of the trial. Nationally, the research team, which is supported by the NIHR Oxford Biomedical Research Centre, is seeking to recruit around 6,000 patients with early signs and symptoms that may indicate cancer.

These patients will have been referred by their GP for rapid diagnostic tests looking for cancer and a Galleri blood sample will also be taken.

In addition to SIMPLIFY, the NHS is piloting the test in primary care settings in a trial called the NHS Galleri trial, which will screen 140,000 people for cancer using the test. The trial will invite people between the ages of 50 and 77 who have not been diagnosed with, or treated for, cancer in the past three years.

Using revolutionary next-generation sequencing technology, the Galleri blood test, which has a false positive rate of less than 1 percent, can detect more than 50 different types of cancers at earlier stages of disease compared with traditional diagnostic methods, which should increase the chance of successful treatment and improve outcomes for patients. Most of these types of cancer have no recommended screening in the UK today.

The Galleri test has been developed by the healthcare company GRAIL.

lead researcher from the University of Oxford, Professor Mark Middleton, the Oxford BRC’s Co-theme Lead for Cancer, said: “The process of diagnosing cancer can often be lengthy and involve expensive imaging or invasive biopsies specific to only one cancer. Often this happens after a patient presents with symptoms and a cancer is more progressed.

“If we can intervene at an earlier stage and detect a cancer using minimally invasive tests, such as Galleri, we have the potential to accelerate cancer diagnoses and reduce the number of diagnostic procedures. Ultimately these tests could transform cancer patient care within the next five years by improving the chance of successful treatment and survival.”

← First person receives drug designed to re-sensitise patients to cancer treatment
Cancer Research UK to invest £11 million into cancer science in Oxford →

News

  • Study highlights ongoing COVID-19 risk in some cancer patients despite vaccination 24 May 2022
  • BRC study outlines researchers training needs and barriers 20 May 2022
  • Three new Blood and Transplant Research Units created in Oxford 18 May 2022
See full news archive

News Categories

Month Archives

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced several times a year and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Oxford BRC on Social Media

  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Feedback

We’d love to hear your feedback. Please contact us at obrcenquiries@ouh.nhs.uk

  • Sitemap
  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2022 NIHR Oxford Biomedical Research Centre